The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Agomelatine Versus Venlafaxine XR in the Treatment of Anhedonia in Major Depressive Disorder: A Pilot Study
Abstract
The primary aim of the present study was to compare the effects of agomelatine (AGO) and venlafaxine XR (VLX) on anhedonia in patients with major depressive disorder. Secondary end points were to test its antidepressant and anxiolytic efficacy.Sixty patients were enrolled and randomly assigned to two different treatments: AGO (25-50 mg/d; n = 30 subjects) or VLX (75-150 mg/d, n = 30 subjects). Psychopathological assessment was performed at baseline and after 8 weeks of treatment with the Snaith Hamilton Rating Scale (SHAPS), the Hamilton Depression Rating Scale, the Hamilton Anxiety Rating Scale, and the Clinical Global Impression for anhedonia, depression, anxiety, and global improvement, respectively.Both groups showed a significant reduction in time for the SHAPS, the Hamilton Depression Rating Scale, and the Hamilton Anxiety Rating Scale. A significant between-group difference was observed for SHAPS scores: patients treated with AGO showed a more relevant reduction compared with that in VLX-treated patients. Moreover, only patients treated with AGO showed a statistically significant improvement in Clinical Global Impression scores.In this study, AGO showed significantly greater efficacy on anhedonia and similar antidepressant efficacy to the serotonin-norepinephrine reuptake inhibitor VLX in patients with major depressive disorder during an 8-week treatment period. Anhedonia has been considered a potential trait marker related to vulnerability for depression. Therefore, the efficacy of AGO on this dimension holds particular importance in the treatment of patients with anhedonic features.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, findings from both emotional blunting and anhedonia studies suggest that switching from SSRI/SNRIs to other monoaminergic agents or multimodal antidepressants could be a promising maneuverer for managing emotional blunting (62, 63).”
From Emotional Blunting in Patients With Major Depressive Disorder: A Brief Non-systematic Review of Current Research (2021) · cites this paper as [62]
In the citing paper
“Agomelatine, which acts via the melatonergic system (MT1 and MT2 agonist) and as a antagonist on the 5-HT2C receptor, has shown promising results in a number of studies in this context (Kasper and Hamon, 2009; Di Giannantonio et al., 2011; Martinotti et al., 2012; Gargoloff et al., 2016).”
From Circuit Mechanisms of Reward, Anhedonia, and Depression (2019) · cites this paper as Martinotti et al., 2012
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
The Neural Correlates of Anhedonia in Major Depressive Disorder
Keedwell, P. A., Andrew, C., Williams, S. C. R., Brammer, M. J., & Phillips, M. L. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.019 · Cited by 650
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
The Medical Management of Depression
Mann, J. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050730 · Cited by 421
L??o, H., Hale, A., & D??haenen, H. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200209000-00004 · Cited by 361
Hedonic capacity: some conjectures.
Meehl, P. E. (1975) · PubMed · Cited by 321
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
Kennedy, S. H., & Emsley, R. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.09.002 · Cited by 294
Effect of Agomelatine in the Chronic Mild Stress Model of Depression in the Rat
Papp, M., Gruca, P., Boyer, P.-A., & Mocaër, E. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300091 · Cited by 268
Pierre Olié, J., & Kasper, S. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007766 · Cited by 256
Spijker, J., Bijl, R. V., De Graaf, R., & Nolen, W. A. (2001) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2001.103002122.x · Cited by 254
Novel naphthalenic ligands with high affinity for the melatonin receptor
Yous, S., Andrieux, J., Howell, H. E., Morgan, P. J., Renard, P., Pfeiffer, B., Lesieur, D., & Guardiola-Lemaitre, B. (1992) · Journal of Medicinal Chemistry · doi:10.1021/jm00086a018 · Cited by 234
Lemoine, P., & Guilleminault, C. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1112 · Cited by 217
Kennedy, S. H., Rizvi, S., Fulton, K., & Rasmussen, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b48c · Cited by 212
Montgomery, S. A., Kennedy, S. H., Burrows, G. D., Lejoyeux, M., & Hindmarch, I. (2004) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000137184.64610.c8 · Cited by 196
Ribot, T., & Nicolas, S. (2005) · Cited by 160
Sleep disturbances and depression: a challenge for antidepressants
Lam, R. W. M. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000195658.91524.61 · Cited by 158
Alcohol Protracted Withdrawal Syndrome: The Role of Anhedonia
Martinotti, G., Nicola, M. D., Reina, D., Andreoli, S., Focà, F., Cunniff, A. L., Tonioni, F., Bria, P., & Janiri, L. (2008) · Substance Use & Misuse · doi:10.1080/10826080701202429 · Cited by 148
Self-citationTaylor, D. J., Walters, H., Vittengl, J. R., Krebaum, S. R., & Jarrett, R. B. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.08.007 · Cited by 121
Zajecka, J., Schatzberg, A. F., Stahl, S. M., Shah, A., Caputo, A., & Post, A. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181d420a7 · Cited by 117
Martinotti, G., Nicola, M. D., Giannantonio, M. D., & Janiri, L. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089596 · Cited by 104
Self-citationMartinotti, G., Andreoli, S., Reina, D., Nicola, M. D., Ortolani, I., Tedeschi, D., Fanella, F., Pozzi, G., Iannoni, E., D'Iddio, S., et al. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.01.013 · Cited by 104
Self-citationThe Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine
Berardis, D. D., Iorio, G. D., Acciavatti, T., Conti, C. M., Serroni, N., Olivieri, L., Cavuto, M., Martinotti, G., Janiri, L., Moschetta, F. S., et al. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794488674 · Cited by 83
Self-citationAgomelatine Treatment of Major Depressive Disorder
Dolder, C. R., Nelson, M., & Snider, M. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1l296 · Cited by 79
Major depressive disorder, anhedonia and agomelatine: an open-label study.
Giannantonio, M. D., Iorio, G. D., Guglielmo, R., Berardis, D. D., Cm, C., Acciavatti, T., Cornelio, M., & Martinotti, G. (2011) · PubMed · Cited by 72
Self-citationDepression and associated sleep disturbances: patient benefits with agomelatine
Kupfer, D. J. (2006) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(06)70010-4 · Cited by 58
Chronotherapeutics and psychiatry: Setting the clock to relieve the symptoms
Coogan, A. N., & Thome, J. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.598389 · Cited by 54
Agomelatine for the treatment of major depressive disorder
Carney, R. M., & Shelton, R. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.607812 · Cited by 50
[Anhedonia in psychiatry: a review].
Loas, G., & Pierson, A. (1989) · PubMed · Cited by 43
Major depressive disorder, anhedonia, and agomelatine: An open-label study
Martinotti, G., Iorio, G. D., Guglielmo, R., Berardis, D. D., Janiri, L., & Giannantonio, M. D. (2011) · European Psychiatry · doi:10.1016/s0924-9338(11)72356-2 · Cited by 36
Self-citationHaloperidol alters circadian clock gene product expression in the mouse brain
Coogan, A. N., Papachatzaki, M. M., Clemens, C., Baird, A. L., Donev, R., Joosten, J., Zachariou, V., & Thome, J. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.543149 · Cited by 17
The effects of reboxetine on human sleep architecture in depression: preliminary results
Farina, B., Marca, G. D., Mennuni, G. F., Mazza, S., Risio, S. D., & Giannantonio, M. D. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00366-4 · Cited by 16
Agomelatine: An Antidepressant Without Deterioration of Sexual Response
Sapetti, A. (2012) · Journal of Sex & Marital Therapy · doi:10.1080/0092623x.2011.613095 · Cited by 10
Cited by
Dopamine system dysregulation in major depressive disorders
Belujon, P., & Grace, A. A. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx056 · Cited by 754
“In patients, both venlafaxine (serotonin and norepinephrine reuptake inhibitor) and agomelatine decreased the score of MDD patients on the Hamilton depression scale as well as the Hamilton anxiety scale (Martinotti et al., 2012).”
BackgroundMethodAssessing anhedonia in depression: potentials and pitfalls
Rizvi, S. J., Pizzagalli, D. A., Sproule, B. A., & Kennedy, S. H. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.03.004 · Cited by 571
“Consistent with this notion, both the SHAPS and FCPS have demonstrated ability to measure acute changes in anhedonia (Martinotti et al, 2012; Willner et al, 2005).”
ResultCircuit Mechanisms of Reward, Anhedonia, and Depression
Höflich, A., Michenthaler, P., Kasper, S., & Lanzenberger, R. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy081 · Cited by 253
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants
Khoo, A. L., Zhou, H. J., Teng, M., Lin, L., Zhao, Y. J., Soh, L. B., Mok, Y. M., Lim, B. P., & Gwee, K. P. (2015) · CNS Drugs · doi:10.1007/s40263-015-0267-6 · Cited by 228
Metadata
- Authors
- Martinotti, G., Sepede, G., Gambi, F., Di Iorio, G., De Berardis, D., Di Nicola, M., Onofrj, M., Janiri, L., & Di Giannantonio, M.
- Affiliations
- University of Chieti-Pescara (IT)
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Martinotti, Giovanni
- Sepede, Gianna
- Gambi, Francesco
- Onofrj, Marco
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2012-08
- Volume
- 32
- Issue
- 4
- Pages
- 487-491
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2084674758
- Cited by
- 276
- References
- 37
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 5 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 161 · 2019: 13 · 2018: 5 · 2017: 8 · 2016: 11 · 2015: 17 · 2014: 8 · 2013: 13 · 2012: 5
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- agomelatine, venlafaxine, major depressive disorder, anhedonia, antidepressant efficacy, anxiolytic efficacy, serotonin-norepinephrine reuptake inhibitors, melatonin receptor agonists
- MeSH terms
- Venlafaxine Hydrochloride, Acetamides, Adolescent, Adult, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Depressive Disorder, Major, Female, Humans, Hypnotics and Sedatives, Male, Middle Aged, Naphthalenes, Patient Dropouts, Pilot Projects, Psychiatric Status Rating Scales, Antidepressive Agents, Second-Generation, Anhedonia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.